Nexovas5 mg

Nexovas 5 mg is used for the management of hypertension (high blood pressure), including for end-organ protection. It is used to treat mild to moderate essential hypertension, either alone or together with other antihypertensive medicines.

Contains Nexovas 5 mg as the active ingredient, available as oral tablets, commonly in strengths of 5 mg, 10 mg, or 20 mg. Exact strengths available may vary by product.

Nexovas 5 mg is a calcium channel blocker medicine used to treat high blood pressure. It belongs to the dihydropyridine class but is distinctive in that it blocks both L-type calcium channels in blood vessels and N-type calcium channels in sympathetic nerve endings. This dual action relaxes blood vessels to lower blood pressure while also reducing the reflex increase in heart rate that is often seen with other calcium channel blockers.

Therapeutic Class: Calcium Channel Blocker (Antihypertensive)

Nexovas 5 mg is well absorbed orally and undergoes extensive hepatic metabolism, with elimination mainly through the biliary/fecal route. Its peak plasma concentration is typically reached within about 1.5 to 4 hours after oral dosing. Unlike many other dihydropyridine calcium channel blockers, Nexovas 5 mg's additional blockade of N-type calcium channels on sympathetic nerve terminals reduces norepinephrine release, which helps blunt the reflex tachycardia commonly associated with vasodilation.

Nexovas 5 mg tablets are taken orally, usually once daily after breakfast, swallowed whole with water. Taking the dose at a consistent time each day helps maintain steady blood pressure control.

Nexovas 5 mg may interact with the following, and combined use should be assessed by a healthcare professional:

• Other antihypertensive medicines, which may increase the blood-pressure-lowering effect
• Antipsychotic medicines that can cause hypotension
• Quinidine, phenytoin, and carbamazepine
• Rifampicin, which may reduce Nexovas 5 mg levels through enzyme induction
• Cimetidine and erythromycin, which may increase Nexovas 5 mg levels

Common side effects

• Dizziness
• Flushing
• Headache
• Hypotension (low blood pressure)
• Peripheral edema (swelling of the ankles or feet)
• Palpitations
• Gastrointestinal disturbances
• Increased frequency of urination

Less common side effects

• Lethargy
• Eye pain
• Low mood

Seek medical attention if chest pain occurs after starting Nexovas 5 mg, or for signs of a severe allergic reaction.

Pregnancy

Nexovas 5 mg should not be given to pregnant women or women who may be pregnant, as safety in human pregnancy has not been established.

Breastfeeding

Nexovas 5 mg is generally advised to be avoided in breastfeeding mothers. If treatment with Nexovas 5 mg is considered essential, the mother should be advised to discontinue breastfeeding, based on manufacturer guidance.

• Use with caution in patients with hypotension, poor cardiac reserve, or heart failure.
• Nexovas 5 mg should be discontinued if the patient experiences ischemic chest pain following administration.
• Sudden withdrawal should be avoided, as this may worsen angina in susceptible patients.
• Use with caution in patients with significant hepatic dysfunction, since the drug is extensively metabolized by the liver.
• Not recommended in pregnancy or breastfeeding.

Overdose with Nexovas 5 mg, as with other calcium channel blockers, may cause pronounced hypotension, reflex or, in some cases, slowed heart rate, and dizziness or fainting. Overdose is a medical emergency requiring urgent evaluation and supportive treatment in a healthcare facility; symptomatic patients should seek immediate medical care.

Store at room temperature, protected from light and moisture, as specified on the product packaging. Keep out of reach of children. Exact storage instructions may vary by manufacturer; follow the specific product's label.

• Elderly: Nexovas 5 mg is reported to be useful in elderly hypertensive patients; use with routine monitoring of blood pressure and cardiac status.
• Diabetes and chronic kidney disease: Nexovas 5 mg has been used in hypertensive patients with diabetes, albuminuria, or chronic kidney disease, often as part of combination therapy, under specialist guidance.
• Hepatic impairment: Use with caution due to extensive hepatic metabolism.

Nexovas 5 mg is generally used long-term as maintenance therapy for chronic hypertension, with the duration determined by ongoing blood pressure control and the physician's assessment. It should not be stopped abruptly without medical advice.

Drug Class: Dihydropyridine calcium channel blocker (L-type and N-type)

Nexovas 5 mg relaxes blood vessel walls by blocking L-type calcium channels in vascular smooth muscle, reducing calcium influx and lowering blood pressure. It additionally blocks N-type calcium channels found on sympathetic nerve terminals, which reduces the release of norepinephrine. This second action helps suppress the reflex rise in heart rate that often accompanies blood pressure lowering with typical calcium channel blockers.

Nexovas 5 mg is not established for use in children, as cardiovascular conditions requiring this medicine are rare in the pediatric population and there is no established pediatric dosing recommendation.